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correlates with disease stages. The modified pE-Aβ is first measurable on the brink from preclinical to clinical stage (Rijal Upadhaya et al., 2014; Thal et al., 2015) . These results link the formation and accumulation of N3pE-Aβ to the cognitive status and disease progression of AD. The size and structure of native Aβ oligomers is currently being intensively investigated.
The formation of pE-Aβ is catalysed by the metal-dependent enzyme glutaminyl cyclase (QC) (Schilling et al., 2004) . QC is highly expressed in the human brain and has been shown to be upregulated in AD (Schilling et al., 2008) , thereby causing an increase in pE-Aβ formation.
Likewise, the concomitant accumulation of Aβ also favours formation of pE-Aβ due to increased QC substrate levels. Previous studies showed that expression of human QC in APP transgenic mice increases pE-Aβ formation and induces a behavioural deficit (Jawhar et al., 2011; Nussbaum et al., 2012) , while a depletion of murine QC prevents the development of the AD-like phenotype in 5xFAD transgenic mice (Jawhar et al., 2011) . A pharmacological proof of principle has been shown previously in two different AD mouse models using the QC-inhibitor PBD150 (1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea) as tool compound. The compound prevents the generation of pE-Aβ(3-42) and improves spatial learning and memory (Schilling et al., 2008) .
Within a comprehensive drug discovery program (Buchholz et al., 2006 , Buchholz et al. 2009 Ramsbeck et al. 2013 ), PQ912 (Figure 1 ), has been selected as a development candidate, based on its excellent overall drug-like profile. PQ912 is a first in class inhibitor of glutaminyl cyclases currently being in clinical development (Lues et al., 2015) .
In this paper, we summarise key primary and secondary pharmacological data relevant to evaluate the compound's in vivo efficacy and target occupancy as well as the in vivo substrate selectivity of PQ912 as a basis for the translational assessment of the therapeutic window.
The data support a favourable profile of the compound for QC engagement coupled to a reduction of pE-Aβ and behavioural improvements, setting the cornerstones for translation of the approach to clinical trials.
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and Tg-control group received drug-free food pellets. The effect of the test compound on learning and memory (MWM) was evaluated at an age of approximately 8.5 months. Mice were sacrificed at the age of 9 months and the brain amyloid burden was quantified, applying ELISA for N3pE-Aβ as described below.
Therapeutic short term treatment regimen.
Male and female hAPP SL xhQC double transgenic mice received PQ912 food pellets (0.8 g/kg) for 5 weeks, starting at 7.5 months of age. Animals of the Tg-control group received regular food pellets. The effect of the test compound on learning and memory (MWM) was evaluated at an age of approximately 8.5 months. Mice were sacrificed at the age of 9 months and the brain amyloid burden was quantified.
Therapeutic long-term treatment regimens.
Male and female hAPP SL xhQC double transgenic mice received PQ912 food pellets (0.8 g/kg) for 4 months, starting at 8 months of age. Tg controls received normal food pellets. Tg animals of the control group and non Tg littermates received drug-free food pellets. Mice were sacrificed at the age of 12 months. The brain amyloid burden was quantified, applying ELISA for N3pE-Aβ.
Female 5xFADxhQC mice (Jawhar et al., 2011) received PQ912 orally at doses of 0.8 and 2.4 g/kg food pellets. Treatment was started at 3 months of age. Animals were sacrificed at 6 months of age.
Morris water maze (MWM)
The Morris water maze consisted of a white circular pool (diameter: 100 cm), filled with tap water at a temperature of 21 ± 2°C. The pool was virtually divided into four quadrants. A transparent platform (8 cm diameter) was placed about 0.5 cm beneath the water surface.
During all test sessions the platform was located in the southwest quadrant of the pool. Each mouse had to perform three trials with a time lag of 10 minutes in between (inter-trial time) on each of four consecutive days. A single trial lasted for a maximum of one minute. During this time, the mouse had to find the hidden, diaphanous platform. After each trial, mice were allowed to rest on the platform for 10 -15 seconds to orientate in the surrounding. At least one hour after the last trial on day 4, mice had to fulfil a probe trial (PT). During the PT, the platform was removed from the pool and the number of crossings over the former target position and the abidance in this quadrant was recorded.
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A computerized tracking system was used for the quantification of the escape latency (time in seconds the mouse needs to find the hidden platform and therefore to escape from the water) and of the target zone crossings and the abidance in the target quadrant in the PT. All animals had to perform a visual test after the PT to rule out visual impairments that may influence the results of the MWM test.
Tissue sampling
From Tg mice blood (plasma), CSF and brains were collected. Mice were sedated by standard inhalation anaesthesia (Isoba ® , Essex). Cerebrospinal fluid was obtained by blunt dissection and exposure of the foramen magnum. Upon exposure, a Pasteur pipette was inserted to the approximate depth of 0.3 -1 mm into the cisterna magna. CSF was collected by suction and capillary action until flow fully ceased. CSF samples were immediately frozen on dry ice and stored at -80°C. After CSF sampling, each mouse was placed in dorsal position, thorax was opened and a 26-gauge needle attached to a 1 cc syringe was inserted into the right cardiac ventricular chamber. Blood was collected into EDTA coated vials and used to obtain plasma.
To get plasma, blood samples from each mouse were centrifuged (1000 x g, 10 min, room temperature). Following blood sampling, mice were transcardially perfused with physiological (0.9 %) saline. Thereafter, brains were removed and cerebellum was cut off and stored at -80°C. Brains were hemisected and immediately frozen on dry ice. One brain hemisphere was used for determination of Aβ level by ELISA and cerebellum and CSF were used for measurement of compound exposure using LC-MS/MS.
Analysis of N3pE-Aβ42
Brain tissue without cerebellum was homogenised in Tris buffered saline (TBS, 20 mM Tris, 137 mM NaCl, pH 7.6, 2 volumes of buffer per brain weight, Dounce homogenizer) containing protease inhibitor cocktail (Complete Mini, Roche, Basel, Switzerland) and 0.1 mM AEBSF (Carl Roth, Karlsruhe, Germany), sonicated and centrifuged at 75,500 x g for 1 hour at 4°C. The supernatant was stored at -80°C and Aβ peptides were sequentially extracted with 2.5 ml TBS / 1 % Triton X-100 (TBS / Triton fraction), 2.5 ml 2 % SDS in distilled water (SDS fraction), and 0.5 ml 70 % formic acid (FA fraction). The formic acid extract was neutralized by addition of 3.5 M Tris solution and diluted to a final volume of 10 ml using ELISA blocking buffer (Pierce, Cat.No. 37571) . The sum of Aβ determined in the SDS and the FA fractions were considered as the insoluble pool of Aβ. ELISAs detecting Aβ(x-42) and N3pE-Aβ42 (IBL, Hamburg) were performed according to the manufacturer´s manual.
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Samples were diluted to fit within the range of the standard curve using EIA buffer solution, which is supplied with the ELISA kits. Values below LOQ were set to zero.
Statistics
Descriptive statistical analysis was performed on all evaluated parameters. Data were averaged and (if not stated otherwise) represented as mean ± standard error of the mean (SEM). Differences compared to respective control groups were analysed by t-test or ANOVA. In case of non-normally distributed data Kruskal-Wallis test was used. Post-hoc comparisons with the respective control group were done by Dunnett's or Dunn's test. For the MWM outliers detected with Grubb`s test were excluded from data analysis. Differences in MWM learning curves were evaluated by a Two-way ANOVA followed by Dunnett's posttest.
Pharmacokinetics
PK day profile in CSF and brain after one week of treatment PQ912 exposure was determined in a satellite experiment using 10 months old hAPP SL xhQC mice (n = 5) treated for 1 week with chow (ad libitum) containing 0.8 g/kg PQ912 (equivalent to approx. 200 mg/kg/day). On the last day, animals were sacrificed at 5 am, 9 am, 1 pm, 7 pm and 11 pm. CSF, brain and cerebellum were analysed for PQ912 using liquid chromatography hyphenated with tandem mass spectrometry (LC-MS/MS) as described below.
PQ912 concentrations in brain and CSF after long-term treatment PQ912 exposure was determined in cerebellum and CSF of hAPP SL xhQC mice treated for 6 months with chow (ad libitum) containing 0.24, 0.8 and 2.4 g/kg PQ912. Animals were sacrificed in the morning after 6 weeks (0.8 g/kg only) or 6 months treatment and CSF and cerebellum samples were analysed for PQ912 using LC-MS/MS.
Determination of free brain concentration
The free concentration of PQ912 in brain was determined using equilibrium dialysis in vitro.
PQ912
(1 µM final concentration) was spiked into buffer diluted mouse brain homogenate and buffer and added to either side of the membrane of the equilibrium device (RED, Thermo Scientific). After equilibration at 37°C for 4 hours, the compound concentration on both sides 
Bioanalysis with LC-MS/MS
Brain hemispheres or cerebellum samples were homogenized in 2 volume equivalents of 90 % acetonitrile using a Precellys® 24 homogenizer containing 1.4 mm ceramic beads. After centrifugation, the supernatant was further diluted with 90 % acetonitrile containing the stable isotope labelled internal standard.
CSF and in vitro samples were extracted with 3 volume equivalents of acetonitrile containing the stable isotope labelled internal standard.
Quantification of PQ912 in CSF, brain homogenate and buffer extracts was done using a specific and sensitive LC-MS/MS method. After protein precipitation and centrifugation, an aliquot of extracts (2 µl) was injected onto a Synergi Polar RP column (50 x 2 mm, 2.5 µm, Phenomenex) and separated using a linear gradient of water / acetonitrile from 5 % to 95 % organic within 4 minutes at 0.3 ml/min (HP1200, Agilent). PQ912 was quantified in the 
Secondary Pharmacology
In order to assess an influence of treatment on pE-hormone maturation, we determined the concentration of the hormones testosterone and thyrotropin (TSH) and thyroxin (T4) in plasma. The production of the thyroid and the gonadal hormones are regulated by the hypothalamic pituitary thyroid (HPT) or the hypothalamic pituitary gonadal (HPG) axes, respectively. Mice (C57/Bl6) were treated orally for 2 weeks receiving food pellets containing PQ912 at doses of 2.4 g/kg and 4.8 g/kg. Afterwards, animals were sacrificed and blood plasma was prepared. Specific ELISAs were used according to the instructions of the manufacturer for determination of TSH (Cusabio, #SY45021), T4 (#RE55261) and testosterone (#RE52151) (IBL, Hamburg, Germany). 
RESULTS
In vitro Binding Studies
Mammalian glutaminyl cyclases are metalloenzymes that contain a typical architecture of a catalytic zinc binding motif. PQ912 showed competitive inhibition of human QC activity ( Figure 1 ) with a K i -value of about 25 nM (pH 8.0). Similar K i -values were found for inhibition of recombinant murine QC (Table 1 ). The binding constant of PQ912 for human QC was also determined using surface plasmon resonance technology. PQ912 showed fast association and dissociation kinetics with a K D -value of 17 nM. The koff-value of 0.023 s -1 corresponds to a half-life of the QC-inhibitor complex of about 30 seconds.
Cellular assays
The effect of human QC inhibition on formation of N3pE-Aβ40 was determined using a cellular assay, which is based on expression of human APP variants (Table 2) 
PQ912 exposure and target occupancy in hAPP SL xhQC mice
The PQ912 exposure in CSF and brain of hAPP SL xhQC mice after oral application of PQ912 (0.8 g/kg chow, ad libitum) is shown in Figure 3 . At this dose, the mean free PQ912 concentration was about 2 times K i (47 nM for CSF and 56 and 62 nM for brain and cerebellum homogenate, respectively), resulting in a mean target occupancy of more than 60 % (65, 69, and 71 % for CSF, brain and cerebellum, respectively).
Previous studies in 5xFAD mice crossbred with QC knockout mice (Jawhar et al., 2011) implied that more than 50 % QC inhibition is required to achieve an effect on pE-Aβ formation and a concomitant behavioural improvement (unpublished observations). Hence, doses of 0.24, 0.8 and 2.4 g were selected for further long-term treatment.
The treatment of hAPP SL xhQC mice for 6 months resulted in brain concentrations of about 50, 230 and 700 ng/g brain, respectively (Figure 4) . Considering an unbound fraction of 0.06 ± 0.02 (n = 3), the free brain concentrations corresponded well with the PQ912 concentrations in CSF. Thus, these data suggest that an oral dose of 0.8 g/kg is sufficient to achieve more than 60 % inhibition of QC in brain over 24 h.
Pharmacodynamic effects of PQ912 in Transgenic Mice
Two AD-like mouse models were used to assess the in vivo effect of PQ912, the double transgenic hAPP SL xhQC mice and the 5xFADxhQC mice. The 5xFADxhQC mice were characterized in a previous study (Jawhar et al., 2011) . These mice start to develop pE-Aβ containing deposits at an age of 3 to 4 months. Also hAPP SL xhQC mice have been briefly described previously (Nussbaum et al., 2012) , but a detailed characterization of pE-Aβ deposition and behavioural changes at different age for these mice was lacking. The development of AD pathology reflected by pE-Aβ increase in the brain and deficits in behavioural tests was evaluated in a longitudinal study as basis for the definition of prophylactic treatment versus therapeutic treatment paradigms ( Figure 5 ). PQ912 was then tested for reduction of pE-Aβ formation in hAPP SL xhQC or 5xFADxhQC mice in both treatment paradigms. Furthermore the effect of PQ912 on learning and memory was assessed in the hAPP SL xhQC mice.
The deposition of Aβ in hAPP SL xhQC transgenic mice starts at an age of about 6 months and increases continuously with age. There was a 3 to 4-fold increase of total Aβ between 9 and 12 months reaching similar levels in hAPP SL single transgenic and hAPP SL xhQC double Figure 5A ). N3pE-Aβ is detectable in some animals above lower level of quantification for the first time at an age of about 7.5 months and present in all animals at 9 months of age ( Figure 5B ). pE-Aβ is progressively accumulating during ageing in single transgenic hAPP SL (≈ 15-fold increase between 9 and 12 months) and especially in the double transgenic hAPP SL xhQC mice (≈ 30-fold increase), resulting in significantly more N3pE-Aβ in the brains of the double transgenic mice.
First behavioural changes of the double transgenic mice in the Morris water maze are detected already at 4 months of age (data not shown), thus slightly preceding the presence of pE-Aβ at quantifiable concentrations. Double transgenic mice perform clearly worse in the Morris water maze between 6 and 9 months of age ( Figure 5C to F). Therefore, preventive treatment was initiated before onset of pathophysiological changes, e.g. at an age of 3 months and therapeutic paradigms began after detection of behavioural or pathological changes, at 7 to 8 months of age.
Preventive long-term treatment
In this set of experiments, transgenic mice were treated orally beginning at 3 months of age.
PQ912 was applied via food pellets containing 0.24, 0.8 or 2.4 g compound per kg of chow.
Behavioural assessment in the Morris water maze test was performed at 8.5 months of age.
The animals were sacrificed 2 weeks later and brain tissue was collected for analysis of compound concentration and Aβ content.
After sacrifice, Aβ was sequentially extracted from brain hemispheres as described above using TBS, SDS and formic acid. The concentration of N3pE-Aβ42 within the TBS fraction is depicted in Figure 6A . The treatment with PQ912 resulted in a significant reduction of N3pE-Aβ42 in the TBS extracts at a dose of 0.8 and 2.4 g PQ912 per kg chow. The reduction of N3pE-Aβ42 within the fractions of the insoluble pool (SDS and formic acid summed up) did not reach significance (data not shown).
For the behavioural assessment, wild type littermates were used as naïve (non Tg-control) control. The effect of PQ912 was compared to vehicle treated transgenic animals (Tgcontrol). At an age of 8.5 months, wt animals were able to learn to find the target position, 
Therapeutic short term treatment
In an additional arm of the same study, hAPP SL xhQC mice were treated with a PQ912 dose of 0.8 g/kg chow beginning at about 7.5 months of age. The study was performed in order to assess, whether a short treatment period might already result in biochemical changes and a behavioural improvement of the mice. The Morris water maze test was performed after 3 weeks of treatment, thus, animal age matched with the previous analysis of the preventive long term treatment. Subsequently animals (9 months of age) were sacrificed for biochemical analysis. This short term treatment with the QC-inhibitor PQ912 did not affect the N3pE-Aβ42 concentration in brain ( Figure 7A ). However, the treatment caused an improvement of spatial learning abilities compared to vehicle treated hAPP SL xhQC double transgenic controls, shown by significantly shorter escape latencies on day 3 and day 4 ( Figure 7B ). With regard to spatial learning, short term treated animals showed a comparable abidance in the target quadrant as long term treated animals. The effect on spatial memory as assessed in the probe trial, did not reach significance ( Figure 7C ).
Therapeutic long-term treatment
In an additional set of experiments, we assessed the effect of PQ912 at a dose of 0.8 g/kg food pellets for 4 months, starting at 8 months of age. The treatment resulted in a clear reduction of We also investigated the effect of PQ912 in 5xFADxhQC mice, which has also been used in a genetic proof of concept study (Jawhar et al., 2011) . Because these mice start to develop plaques at 2 to 3 months of age, i.e. earlier than hAPP SL xhQC, we treated these animals from 3 to 6 months. The total pE-Aβ load in the brain of vehicle-treated animals was similar to 12 months old hAPP SL xhQC mice (Figure 8 In vivo secondary pharmacology related to substrate specificity -HPT and HPG axis As indicated in the introduction, physiological substrates of QC carry an N-terminal glutamine (Gln) residue without exception, being cyclised by QC to produce pE at the Nterminus. The conversion of N-terminal glutamate residues (Glu) however, seems to be restricted to pathological situations such as accumulation of Aβ in AD. To assess an in vivo therapeutic window between pathological Glu-and physiological Gln-cyclisation, the effect of PQ912 on testosterone and thyroxin (T4) was measured in male C57/Bl6 mice after 2 weeks of treatment. These hormones function as indicators for the maturation of hypothalamic pGlu-hormones gonadoliberin (GnRH) and thyroliberin (TRH) regulating the hypothalamicpituitary-gonadal (HPG) or hypothalamic-pituitary-thyroid (HPT) axis, respectively.
Because the pharmacological experiments pointed towards an efficient reduction of pE-Aβ formation and an accompanying behavioural improvement at a dose of 0.8 g PQ912/kg food pellet, 3-and 6-times higher doses of PQ912 were used (2.4 g/kg food pellet and 4.8 g/kg food pellet). Afterwards, animals were sacrificed and the hormone concentrations in plasma were assessed. With these doses, the downstream hormones of the HPT and HPG axes, testosterone and T4 were not affected by the treatment (Figure 9 ), suggesting that a possible partial inhibition of the maturation of hypothalamic pE-hormones (GnRH and TRH) is compensated at doses that are 6-fold higher than an effective dose for inhibition of pE-Aβ formation.
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DISCUSSION
Compelling evidence suggests a crucial role of N-terminally truncated and pE-modified Aβ in Alzheimer's disease (Bayer and Wirths, 2014; Russo et al., 2002; Gunn et al., 2010) . These modified peptides have been shown to correlate with progression of AD and tau pathology (Thal et al., 2015 , Güntert et al., 2006 , Morawski et al., 2014 , Mandler et al., 2014 . The Nterminal blockage by pE stabilizes against degradation (Saido et al. 1995 , Russo et al. 2002 and increases the surface hydrophobicity of oligomeric aggregates, which is most probably linked to toxicity (Schlenzig et al., 2012) . It was also shown that pE-Aβ facilitates the formation of hetero-oligomers, inducing toxicity in a tau-dependent manner (Nussbaum et al., The aim of the present study was twofold: Firstly, we aimed at determining an effective dose of PQ912, which results in reduction of pE-Aβ formation and concomitant behavioural improvement of transgenic mice. These data provide a key translational finding for the clinical assessment of PQ912 in humans. Secondly, we addressed a potential functional selectivity for inhibition of pE-formation from N-terminal glutamic acid over glutamine.
Glutamate3-Aβ represents the precursor of N3pE-Aβ, while glutamine is the precursor of Nterminal pE in all physiological substrates, among those TRH and GnRH. Therefore, the results should provide evidence for a reasonable therapeutic window.
To assess the efficacy in vivo, we used the hAPP SL xhQC and 5xFADxhQC mouse models.
These mice generate pE-Aβ at higher levels than other mouse models, and the appearance of pE-Aβ is linked to behavioural changes in spatial learning and memory, beginning at an age of 4 to 6 months ( , 2011) . This indicates that the average QC-inhibition necessary to obtain a robust therapeutic effect should be higher than 50 %. Thus, our studies in transgenic mice highlight an effective brain exposure that can be used for translation to human trials. Results of a phase 1 study with PQ912 in healthy volunteers suggested that with well tolerated doses an average QC inhibition in CSF of 90 % could be achieved (Lues et al., 2015) . QC has physiological substrates, which makes it important to evaluate not only the primary pharmacological effect of the cyclisation of the N-terminal glutamic acid residue in N3pE-Aβ but also to assess the effect of PQ912 on those peptides which carry an N-terminal glutamine residue. Reduction of the pE-hormones TRH or GnRH which are generated from Gln precursors results in hypothyroidism or hypogonadism, respectively (Yamada et al., 1997; Mason et al., 1986) . Therefore, the preference of PQ912 to inhibit Glu-over Gln-cyclisation was addressed in a HEK cell model overexpressing different APP constructs as precursors of E3-or Q3-Aβ.
PQ912 effectively inhibited formation of N3pE-Aβ40 from E3-Aβ40 (APP-NLE/hQC), with an EC 50 of about 200 nM. However, the cyclisation of the N-terminal glutamine residue, which is generated by a mutated APP construct leading to Q3-Aβ instead of E3-Aβ (APP-NLQ), was not inhibited with at least 50-fold higher PQ912 concentrations and otherwise identical conditions (overexpression of QC).
Different potential reasons could be considered for that apparent selectivity of PQ912 for inhibition of cyclisation of glutamic acid residues: 1. The difference in the specificity constants of the Glu versus Gln substrates might likely play a role. The apparent dissociation constant (K M ) of Glu substrates was shown to be about 3 orders of magnitude higher compared to the respective Gln-substrates (Seifert et al., 2009; Schilling et al., 2004) . This, in turn, results in enforced competitive replacement of the Glu-substrate by the inhibitor which might account for the apparent specificity of PQ912 to stronger suppress cyclisation of glutamic acid residues. 2. The cyclisation of glutamine residues occurs mainly intracellularly, i.e. under conditions of high substrate and enzyme concentration. Evidence for that was provided by studies on the maturation of peptide hormones (Keire et al., 2003, Nillni and Sevarino, 1999) . These peptides are matured within secretory vesicles and are secreted as the modified pE species. Under these high enzyme / high substrate conditions the excess of substrate "protects" the enzyme from binding the inhibitor so that much higher inhibitor concentrations are needed for considerable inhibition of the Gln cyclisation. Finally, we have previously shown that N-terminal glutamine is prone to spontaneous cyclisation with a halflife of several hours. Thus, spontaneous cyclisation of N-terminal glutamine residues might also contribute to pE formation in physiological substrates. In contrast, N-terminal glutamic acid residues cyclise at negligible rates spontaneously (Seifert et al. 2009 ). All of the aforementioned mechanisms might play a role in vivo causing a higher potency of QC inhibitors to prevent Glu cyclisation.
In order to translate these findings to physiological substrates in vivo, the effect of PQ912 on plasma levels of gonadal and thyroid hormones was assessed in mice treated with PQ912. The secretion of T3 and T4 is regulated by the HPT axis, which also consists of the hypothalamic hormone TRH (pGlu-His-Pro-NH 2 ) and the pituitary hormone TSH. A reduction in mature TRH may occur due to reduction in formation of N-terminal pE in response to QC inhibition.
A pronounced reduction of TRH would result in hypothyroidism, as it is observed in TRH knockout mice (Yamada et al., 1997) . These mice show a 50 % reduction of the thyroxine concentration, increased TSH concentration and hyperglycaemia. Homozygous QC knockout mice show a very mild hypothyroidism as suggested by a 20 % reduction of thyroxin, virtually no effect on TSH and no hyperglycaemia. The effect is likely caused by a reduction of mature pE-TRH (Schilling et al., 2011) .
In order to estimate the therapeutic window based on the differences in inhibition of pE formation in Gln-and Glu-substrates, we assessed TSH, thyroxine and testosterone in plasma of mice treated with high doses of PQ912. Importantly, we did not observe an effect on testosterone as well as on the TSH and thyroxin concentration, even after treatment with a dose 6-fold higher than an efficacious pharmacological dose (Figure 9 ) necessary for inhibition of pE-Aβ formation. This corresponds with results in the multiple ascending dose Phase 1 study, where T3/T4 levels were not affected at a dose, which leads on average to 90 JPET #240614 22 % QC-inhibition in the spinal fluid. Thus, the apparent specificity of PQ912 on cyclisation of Glu-residues opens a therapeutic window for effectively reducing the pE-Aβ formation without effect on hormonal regulation cascades. Summarizing, our results suggest a robust therapeutic effect of PQ912 in transgenic mouse models of AD. These data further strengthen the hypothesis that the formation of pE-Aβ can be effectively reduced by inhibition of glutaminyl cyclase, and that brain QC is a drugable target. The therapeutic effect of PQ912 is observed at an oral dose of about 200 mg/kg/day, which translates to about 60 to 70 % brain target occupancy. Notably, these observations match very well with a PK/PD relationship in human Phase 1 studies, which revealed an EC 50 of 30 nM in human CSF (Lues et al., 2015) . Moreover, the results suggest a comfortable therapeutic window for the compound's primary pharmacological effect on pE-Aβ and behaviour in AD animal models versus its effects on hormonal regulation cascades driven by glutamine cyclisation. and 12 months (n = 4 -13 per group, see numbers in columns). Aβ42 was detectable at 6 months in both genotypes (significantly higher in hAPP SL ) and increases over time. No difference between genotypes was found at 7.5, 9 and 12 months of age. N3pE-Aβ42 becomes detectable for the first time at an age of 7.5 months in a part of the animals (3/8 in hAPP SL , 5/7 in hAPP SL xhQC). N3pE-Aβ42 increases dramatically between 9 and 12 months (≈ 15-fold in hAPP SL , ≈ 29-fold in hAPP SL xhQC) resulting in significantly higher N3pE-Aβ42 levels in the double transgenic animals at 12 months of age. 
